Skip to main content
AB Science logo

AB Science — Investor Relations & Filings

Ticker · AB ISIN · FR0010557264 LEI · 969500U43TVR8CCVBJ97 PA Manufacturing
Open in API
Filings indexed 742 across all filing types
Latest filing 2023-03-13 Regulatory Filings
Country FR France
Listing PA AB

About AB Science

https://www.ab-science.com

AB Science is a clinical-stage pharmaceutical company that researches, develops, and markets protein kinase inhibitors for human and veterinary medicine. The company focuses on developing innovative drugs for diseases with high unmet medical needs. Its pipeline is centered on two main compounds: masitinib and AB8939. Masitinib, a highly selective tyrosine kinase inhibitor, is under investigation for treating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, as well as inflammatory diseases like mastocytosis. AB8939 is a microtubule destabilizer being developed for oncology, specifically for Acute Myeloid Leukemia (AML). The company also commercializes masitinib in veterinary medicine under the brand name Masivet®.

Recent filings

Filing Released Lang Actions
AB Science reports a first complete bone marrow response in a relapsed refractory acute myeloid leukemia patient from the very low dose arm of its AB8939 Phase I/II clinical trial (AB18001)
Regulatory Filings Classification · 1% confidence The document is a press release dated March 13, 2023, announcing a case report from a Phase I/II clinical trial (AB18001) evaluating the drug AB8939 in AML patients. It details preliminary efficacy and safety data from the trial, mentions an upcoming webcast to discuss the platform, and includes extensive background information on the drug, the disease, and the company. This content structure—reporting on clinical trial progress, preliminary results, and future investor events—is characteristic of an Earnings Release (ER) or a general press release detailing operational/clinical updates. Since it focuses on clinical trial results and operational updates rather than just summarizing quarterly financials (ER) or being a formal regulatory filing, it fits best as a general announcement of significant operational/clinical progress. However, given the options, it is a detailed announcement of clinical progress and future investor engagement (webcast). It is not a full Annual Report (10-K), an Interim Report (IR), or a simple Earnings Release (ER) which usually focuses only on financial metrics. It is a detailed update on R&D progress. In the context of the provided definitions, this type of detailed clinical/operational update, which is often released outside of standard quarterly reporting cycles, is frequently categorized under general Regulatory Filings (RNS) if no better fit exists, or sometimes grouped with Investor Presentations (IP) if it were a slide deck. Since it is a narrative press release detailing trial progress and announcing a future webcast, and it is not a formal financial report, it is best classified as a general Regulatory Filing (RNS) as a catch-all for significant, non-standard announcements, or potentially an Earnings Release (ER) if the company uses ERs broadly for all major updates. Given the focus on clinical data and the announcement of a webcast, it is a significant corporate update. Since it is not a formal financial report (10-K, IR, ER), RNS is the most appropriate fallback for a major corporate announcement not covered elsewhere. However, many companies issue these clinical updates as 'Earnings Releases' even if they aren't strictly financial results. Given the high level of detail on the trial and the announcement of a webcast, it functions as a major corporate update. I will lean towards RNS as the most accurate fallback for a detailed clinical/operational press release that isn't a formal financial report.
2023-03-13 English
AB Science announced the publication of the masitinib pivotal phase 3 clinical trial in Alzheimer’s Disease in the journal Alzheimer's Research & Therapy
Regulatory Filings Classification · 1% confidence The document is a press release dated February 28, 2023, announcing the publication of results from a pivotal Phase 3 clinical trial (AB09004) of masitinib in Alzheimer's disease in the journal *Alzheimer's Research & Therapy*. It details the study results, mechanism of action, and plans for a confirmatory study (AB21004). This content is characteristic of an announcement regarding clinical trial progress and scientific findings, which is typically disseminated via an Earnings Release (ER) or a general Regulatory Filing (RNS) if no other specific category fits. Since it is a detailed announcement of scientific/clinical progress rather than just financial highlights (ER) or a formal regulatory filing form, and it is not a transcript (CT), presentation (IP), or management discussion (MDA), the most appropriate classification is a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if the company typically bundles such news there. Given the focus is purely scientific/clinical publication, RNS serves as the best general regulatory announcement category, although it is highly specific news. However, since it is a detailed announcement of a major development (publication of pivotal trial results), it often accompanies or substitutes for an Earnings Release in terms of investor communication, but it is not a standard ER which focuses on financial metrics. It is not a report itself (like 10-K or IR). Given the options, RNS (Regulatory Filings - general regulatory announcements) is the most suitable fallback for significant, non-financial, non-meeting related corporate news releases that don't fit other specific categories like M&A or Capital Change. I will lean towards RNS as the best fit for a scientific publication announcement.
2023-02-28 English
AB Science annonce la publication de l’étude clinique pivot de phase 3 avec le masitinib dans la maladie d’Alzheimer dans la revue Alzheimer's Research & Therapy
Regulatory Filings Classification · 1% confidence The document is a press release from AB Science dated February 28, 2023, announcing the publication of positive Phase 3 clinical study results for Masitinib in Alzheimer's disease in the journal *Alzheimer's Research & Therapy*. It details the study outcomes (ADAS-cog scores, safety profile) and discusses the mechanism of action and the upcoming confirmatory Phase 3 study (AB21004). This content—announcing the results of a clinical trial and providing scientific/management commentary—is characteristic of an Earnings Release (ER) or a general announcement related to clinical progress. Since it focuses heavily on the positive results of a specific clinical trial and the scientific rationale, it aligns best with an Earnings Release (ER) which often includes key clinical/operational updates, or potentially an Investor Presentation (IP) if it were structured as slides, but as a formal press release detailing results, ER is the closest fit among the options for disseminating key performance/development milestones. It is not a full Annual Report (10-K), a formal Audit Report (AR), or a simple Dividend Notice (DIV). Given the focus on announcing key results, ER is the most appropriate classification, although it also contains elements of scientific disclosure. Revisiting the definitions: ER is for 'Initial announcement of quarterly/periodical financial results (key highlights only)'. While this is a clinical result announcement, not a financial period result, these types of press releases often serve the same function of disseminating critical, time-sensitive company performance information to the market. If a more specific 'Clinical Trial Result Announcement' existed, that would be ideal. Given the choices, ER is the best fit for a major, positive, time-sensitive announcement of operational/development success that impacts valuation, similar to how earnings highlights function. It is not a Report Publication Announcement (RPA) because it contains the substance of the findings, not just a notice that a report is available.
2023-02-28 French
AB Science annonce le tirage de la seconde tranche de 6 millions d’euros dans le cadre de son contrat de financement avec la Banque Européenne d’Investissement
Capital/Financing Update Classification · 1% confidence The document is a press release announcing that AB Science has drawn down the second tranche of a financing agreement (€6.0 million) from the European Investment Bank (EIB). This announcement details the terms of the loan tranche, including maturity, interest rate, and the issuance of warrants (BSA). This activity directly relates to the company's fundraising, financing activities, and capital structure changes. Reviewing the definitions: - 10-K/IR: Not a full annual or interim financial report. - ER: Not an earnings release; it's a financing update. - DIV/SHA/POS: While it involves warrants (related to capital), the core subject is the receipt of loan funds. - CAP (Capital/Financing Update): This category perfectly matches an announcement detailing the drawing down of a specific tranche of a pre-arranged financing agreement (loan) with a financial institution (EIB). Therefore, the classification is CAP.
2023-01-31 French
AB Science announces the drawdown of the second tranche of 6 million euros under its financing agreement with the European Investment Bank
Capital/Financing Update Classification · 1% confidence The document is explicitly titled as a "PRESS RELEASE" and details the drawdown of the second tranche of a financing agreement with the European Investment Bank (EIB), including specific amounts (€6.0 million), maturity dates, interest rates, and warrant issuance details. This content directly relates to the company's fundraising, financing activities, and capital structure changes. This aligns perfectly with the definition for Capital/Financing Update (CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a general Regulatory Filing (RNS), as it concerns a specific financing event.
2023-01-31 English
AB Science a reçu l’approbation de la Food and Drug Administration (FDA) américaine pour initier l’étude confirmatoire de Phase 3 avec le masitinib dans le traitement des formes progressives de la scl
Regulatory Filings Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces that AB Science has received approval from the US FDA to initiate a Phase 3 confirmatory study for Masitinib in progressive forms of Multiple Sclerosis. This type of announcement, detailing a significant operational or clinical development milestone, is characteristic of an Earnings Release (ER) if it were quarterly results, or more generally, a regulatory/corporate update. Since it is a press release announcing a major regulatory/clinical event (FDA approval for a Phase 3 trial), it is not a full financial report (10-K, IR), a transcript (CT), or a specific management/board change (MANG). It is a high-level announcement of corporate progress. Given the options, 'Earnings Release' (ER) is often used for major periodic announcements, but this is specifically a clinical/regulatory milestone announcement. However, in many classification schemes, significant corporate news releases that are not explicitly defined elsewhere often fall under the general 'Regulatory Filings' (RNS) category if they are not a formal financial filing, or sometimes an 'Earnings Release' (ER) if the company uses this format for all major news. Since the document is a press release announcing a key regulatory/clinical development (FDA approval for a Phase 3 trial), and it is not a formal financial report, a management change, or a dividend notice, the most appropriate general category for significant, non-financial-specific corporate news that is not a formal filing is often RNS, or ER if it's the primary means of public disclosure. Given the content is about clinical trial progression and regulatory approval, which is critical operational news, and it is a press release, it fits best as a general regulatory/corporate announcement. I will classify it as RNS (Regulatory Filings) as it is a general regulatory announcement that doesn't fit the other specific categories like DIV, MANG, or 10-K.
2022-12-29 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.